OrbiMed Genesis GP LLC
SEC CIK 1808744 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| KROS | Keros Therapeutics, Inc. | Dir | 45.1K | — | $11.00M | 2 | 2024-08-13 | 2025-11-21 |
| EWTX | Edgewise Therapeutics, Inc. | Dir, 10% | 14.81M | $15.00M | — | 2 | 2022-09-16 | 2025-04-03 |
| MBX | MBX Biosciences, Inc. | Dir, 10% | 3.21M | $2.02M | — | 1 | 2025-02-14 | 2025-02-14 |
| IRON | Disc Medicine, Inc. | Dir | 941.6K | $3.00M | $32.59M | 5 | 2023-12-12 | 2024-06-17 |
| PMVP | PMV Pharmaceuticals, Inc. | 10% | 0 | — | $10.46M | 2 | 2022-03-29 | 2023-11-22 |
| DMRA | Damora Therapeutics, Inc. | 10% | 186.6K | — | $222.0K | 1 | 2023-04-05 | 2023-04-05 |
| ELVN | Enliven Therapeutics, Inc. | 10% | 8.66M | — | — | 1 | 2023-02-23 | 2023-02-23 |
| JANX | Janux Therapeutics, Inc. | Dir | 231.1K | — | $10.59M | 3 | 2021-12-16 | 2021-12-29 |
| CMPX | Compass Therapeutics, Inc. | Dir, 10% | 3.57M | $18.75M | — | 1 | 2021-11-04 | 2021-11-04 |
Most active insiders at KROS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Schneeberger Daniel | 10% | — | $95.66M |
| 2 | Pontifax (China) IV L.P. | 10% | — | $84.98M |
| 3 | Cho Esther | SVP, GC | — | $123.7K |
| 4 | Seehra Jasbir | CEO, Dir | — | $113.4K |
| 5 | Lerner Lorena Raquel | CSO | — | $100.0K |
| 6 | Regnante Keith | CFO | — | $77.5K |
| 7 | BIENAIME JEAN JACQUES | Dir | $75.8K | — |
| 8 | Knowles Julius | Dir | — | $28.2K |
| 9 | Farzan Nima | Dir | — | $28.2K |
| 10 | Seth Alpna | Dir | — | $28.1K |
| 13 | OrbiMed Genesis GP LLC | Dir | — | — |
Transactions 18
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2025-12-18 | 2025-11-21 | KROS | Keros Therapeutics, Inc. | OrbiMed Genesis GP LLC | Dir | D - Sale to Iss | $17.75 | -214.5K | 45.1K | -83% | -$3.81M |
| MI | 2025-04-04 | 2025-04-03 | EWTX | Edgewise Therapeutics, Inc. | OrbiMed Genesis GP LLC | Dir, 10% | P - Purchase | $20.13 | +496.8K | 14.81M | +3% | +$10.00M |
| MI | 2025-02-19 | 2025-02-14+ | MBX | MBX Biosciences, Inc. | OrbiMed Genesis GP LLC | Dir, 10% | P - Purchase | $10.60 | +190.7K | 3.21M | +6% | +$2.02M |
| MI | 2024-08-15 | 2024-08-13 | KROS | Keros Therapeutics, Inc. | OrbiMed Genesis GP LLC | Dir | S - Sale | $44.01 | -250.0K | 899.2K | -22% | -$11.00M |
| MI | 2024-06-20 | 2024-06-17 | IRON | Disc Medicine, Inc. | OrbiMed Genesis GP LLC | Dir | P - Purchase | $36.00 | +83.3K | 941.6K | +10% | +$3.00M |
| D | 2023-12-20 | 2023-12-18 | IRON | Disc Medicine, Inc. | OrbiMed Genesis GP LLC | Dir | M - OptEx | $38.00 | +1,724 | 1,724 | New | +$65.5K |
| D | 2023-12-20 | 2023-12-18 | IRON | Disc Medicine, Inc. | OrbiMed Genesis GP LLC | Dir | S - Sale+OE | $59.24 | -1,724 | 0 | -100% | -$102.1K |
| MI | 2023-12-15 | 2023-12-14 | IRON | Disc Medicine, Inc. | OrbiMed Genesis GP LLC | Dir | S - Sale | $56.75 | -433.2K | 897.6K | -33% | -$24.58M |
| MI | 2023-12-14 | 2023-12-12+ | IRON | Disc Medicine, Inc. | OrbiMed Genesis GP LLC | Dir | S - Sale | $58.88 | -134.2K | 727.9K | -16% | -$7.90M |
| I | 2023-11-24 | 2023-11-22 | PMVP | PMV Pharmaceuticals, Inc. | OrbiMed Genesis GP LLC | 10% | S - Sale | $2.23 | -87.8K | 0 | -100% | -$195.8K |
| MI | 2023-04-07 | 2023-04-05+ | DMRA | Damora Therapeutics, Inc. | OrbiMed Genesis GP LLC | 10% | S - Sale | $2.16 | -102.6K | 186.6K | -35% | -$222.0K |
| MI | 2023-02-27 | 2023-02-23 | ELVN | Enliven Therapeutics, Inc. | OrbiMed Genesis GP LLC | 10% | A - Grant | — | +7.90M | 8.66M | +1,037% | — |
| I | 2022-09-16 | 2022-09-16 | EWTX | Edgewise Therapeutics, Inc. | OrbiMed Genesis GP LLC | Dir, 10% | P - Purchase | $10.32 | +484.5K | 13.98M | +4% | +$5.00M |
| MI | 2022-03-31 | 2022-03-29+ | PMVP | PMV Pharmaceuticals, Inc. | OrbiMed Genesis GP LLC | 10% | S - Sale | $21.63 | -474.5K | 34.5K | -93% | -$10.26M |
| MI | 2021-12-30 | 2021-12-29 | JANX | Janux Therapeutics, Inc. | OrbiMed Genesis GP LLC | Dir | S - Sale | $20.30 | -40.4K | 231.1K | -15% | -$820.1K |
| MI | 2021-12-23 | 2021-12-21 | JANX | Janux Therapeutics, Inc. | OrbiMed Genesis GP LLC | Dir | S - Sale | $19.00 | -119.4K | 234.8K | -34% | -$2.27M |
| MI | 2021-12-17 | 2021-12-16 | JANX | Janux Therapeutics, Inc. | OrbiMed Genesis GP LLC | Dir | S - Sale | $19.07 | -393.3K | 245.9K | -62% | -$7.50M |
| MI | 2021-11-08 | 2021-11-04 | CMPX | Compass Therapeutics, Inc. | OrbiMed Genesis GP LLC | Dir, 10% | P - Purchase | $3.50 | +5.36M | 3.57M | New | +$18.75M |
Purchase Sale Sale after option exercise All abbreviations